Breast cancer and the molecular mechanism of estrogen signaling

Abstract

Cancer is a complex pathology that occurs due to the uncontrolled proliferation and growth of cells in any organ or tissue of the body. Breast cancer is the most frequently diagnosed cancer among women worldwide and is the second leading cause of cancer-related deaths. Breast cancer is a pathology that exhibits heterogeneity in which genetic and environmental risk factors play a role. Although many treatment approaches have been developed for breast cancer today, the frequency of the number of patients diagnosed with breast cancer and lost their lives due to this reason is increasing in the world. The most significant limitation to the success of the treatment approaches developing drug resistance in breast cancer cells, and the disease relapses after a certain period and exhibits a more aggressive profile. Therefore, understanding the molecular biology of breast cancer is essential for developing potent therapeutic approaches. It is known that the development of breast cancer is related to changes in direct and indirect signaling mechanisms mediated by estrogen and estrogen receptor. These signaling mechanisms exhibit highly complex interaction patterns. This review summarizes the pathology of breast cancer, estrogenic compounds, estrogen receptors, genomic and non-genomic molecular signaling mechanisms mediated by estrogen and estrogen receptor.

Keywords

• Breast Cancer
• Estrogen
• Estrogen Receptor

References

1. Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183(4):1113-1124. DOI: https://doi.org/10.1016/j.ajpath.2013.08.002
2. Hong R, Ma F, Xu B, Li Q, Zhang P, Yuan P et al. Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs: a single-institute experience. Anti-Cancer Drugs. 2014 Oct;25(9):1089-94. DOI: https://doi.org/10.1097/CAD.0000000000000138
3. Akkaş Gürsoy A. Meme kanserinde eğitimcinin eğitimi programı II kitapçığı, Trabzon. 2005.
4. Aydıntuğ S. Meme kanserinde erken tanı. STED. 2004 Jun;13(6):226-229.
5. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17-48. DOI: https://doi.org/10.3322/caac.21763
6. Gültekin M, Boztaş G, Utku EŞ, Ergün AK, Sevinç A, Tütüncü S ve ark. Türkiye kanser istatistikleri. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu, 2014 Ocak;43:12-32.
7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA:Cancer J Clın. 2018;394–424. DOI: https://doi.org/10.3322/caac.21492
8. Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013 Jun;5(1):2–8. DOI: https://doi.org/10.3978/j.issn.2072-1439.2013.05.24

9. Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015 Oct 20;314(15):1599-614. DOI: https://doi.org/10.1001/jama.2015.12783
10. Somunoğlu S. Meme kanseri: belirtileri ve erken tanıda kullanılan tarama yöntemleri. Fırat Sağlık Hizmetleri Dergisi, 2009;4(10), 103-122.
11. Koçak S, Çelik L, Özbaş S, Saka DS, Tükün A, Yalçın B. Meme kanserinde risk faktörleri, riskin değerlendirilmesi ve prevansiyon: İstanbul 2010 konsensus raporu. J Breast Health. 2011;7(2):47-67.
12. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM et al. Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124(7):966-78. DOI: https://doi.org/10.5858/2000-124-0966-PFIBC
13. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI et al. Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol. 2002 Sep;20(17):3628-36. DOI: https://doi.org/10.1200/JCO.2002.02.026
14. Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife. 2014 Oct 01;3:e02935. DOI: https://doi.org/10.7554/eLife.02935
15. Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. J Clin Pathol. 2005 Dec;124(1):16-28.DOI: https://doi.org/10.1309/5XW3L8LU445QWGQR Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999 Nov 19;83(6):723-6. DOI: https://doi.org/10.1002/(sici)1097-0215(19991210)83:6<723::aid-ijc4>3.0.co;2-3
16. Grignol VP, Agnese DM. Breast cancer genetics for the surgeon: an update on causes and testing options. J Am Col Surg. 2016 May;222(5):906-14.DOI: https://doi.org/10.1016/j.jamcollsurg.2016.01.005
17. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. PNAS USA. 1988 May;85(9):3044-8. DOI: https://doi.org/10.1073/pnas.85.9.3044
18. Ohlsson RI, Pfeifer-Ohlsson SB. Cancer genes, proto-oncogenes, and development. Exp Cell Res. 1987 Nov;173(1):1-16. DOI: https://doi.org/10.1016/0014-4827(87)90327-2
19. Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene. 1988;3(1):21-31.
20. Børresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkilä R, Jahnsen T et al. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer. 1990 Oct;62(4):585-90.DOI: https://doi.org/10.1038/bjc.1990.334
21. Kreipe H, Feist H, Fischer L, Felgner J, Heidorn K, Mettler L, Parwaresch R. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res. 1993 Apr 15;53(8):1956-61.
22. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010Apr-Jun;1(2):109–26.
23. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008 Aug 05;10(4):67. DOI: https://doi.org/10.1186/bcr2128
24. Pinder SE. Ductal carcinoma in situ (DCIS): Pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol. 2010 May 03;23(2):8-13. DOI: https://doi.org/10.1038/modpathol.2010.40
25. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004 Jun 16;96(12):906-20. DOI: https://doi.org/10.1093/jnci/djh164
26. Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive Lobular vs. Ductal Breast Cancer: a stage-matched comparison of outcomes. Breast Oncology. 2010 Jul;17:1862-9. DOI: https://doi.org/10.1245/s10434-010-0953-z
27. Mersin H, Yıldırım E, Gülben K, Berberoğlu U. Is invasive lobular carcinoma different from invasive ductal carcinoma? EJSO. 2003 May;29(4), 390–5. DOI: https://doi.org/10.1053/ejso.2002.1423
28. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005 Jan 1;23(1):41-8.  DOI: https://doi.org/10.1200/JCO.2005.03.111
29. Nursal AF. Molecular basis of the triple negative breast cancer. Archives Med Rev J. 2015; 24(2):251.
30. Dijsselbloem N, Berghe WV, De Naeyer A, Haegeman G. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections: multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol. 2004 Sep 15;68(6):1171-85. DOI: https://doi.org/10.1016/j.bcp.2004.05.036
31. Zaitsu M, Narita S, Lambert KC, Grady JJ, Estes DM, Curran EM et al. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol. 2007 Mar;44(8):1977-85. DOI: https://doi.org/10.1016/j.molimm.2006.09.030
32. Puma GL, Puddu V, Tsang HK, Gora A, Toepfer B.. Photocatalytic oxidation of multicomponent mixtures of estrogens (estrone (E1), 17β-estradiol (E2), 17α-ethynylestradiol (EE2) and estriol (E3)) under UVA and UVC radiation: photon absorption, quantum yields and rate constants independent of photon absorp. App Catalysis B: Environmental. 2010 Sep 9;99(3–4):388–97. DOI: https://doi.org/10.1016/j.apcatb.2010.05.015
33. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol. 1982 Jun;59(6):680-6.
34. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005 Aug;8(1):3–63. DOI: https://doi.org/10.1080/13697130500148875
35. Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone responsive human breast cancer in long-term tissue culture. Cancer Res. 1972 Jun;37:1901–7.
36. Holinka CF, Diczfalusy E, Coelingh Bennink HJ. Estetrol: A unique steroid in human pregnancy. J Steroid Biochem Mol Biol. 2008 May;110(1–2):138-43. DOI: https://doi.org/10.1016/j.jsbmb.2008.03.027
37. Küçükzeybek BB, Taşkaynatan H, Sarı AA, Yiğit S, Ballı G, Etit D ve ark. Östrojen-Progesteron reseptörü pozitif ve aksiller lenf nodu negatif meme kanseri tanılı hastalarda ki-67 proliferasyon indeksi. Konuralp Med J. 2018;10(3):387-94.
38. Zhou Z, Qiao JX, Shetty A, Wu G, Huang Y, Davidson NE et al. Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. CMLS. 2014 Apr;71(8):1549. DOI: https://doi.org/10.1007/s00018-013-1376-3
39. Pettersson K, Delaunay F, Gustafsson JÅ. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene. 2000 Oct 12;19:4970-8. DOI: https://doi.org/10.1038/sj.onc.1203828
40. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB. 1996 Apr;10(5):615-24.
41. Jeffreys SA, Powter B, Balakrishnar B, Mok K, Soon P, Franken A et al. Endocrine resistance in breast cancer: the role of estrogen receptor stability. Cells. 2020 Sep 11;9(9):2077. DOI: https://doi.org/10.3390/cells9092077
42. Gu Y, Chen T, López E, Wu W, Wang X, Cao J et al. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors. J Transl Med. 2014 Jan 21;12(1):1-12. DOI: https://doi.org/10.1186/1479-5876-12-16
43. Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling. Biochem Med. 2014 Oct 15;24(3):329-42. DOI: https://doi.org/10.11613/BM.2014.035
44. Le Romancer M, Poulard C, Cohen P,  Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor’s posttranslational code in breast tumors. Endocrine Rev. 2011 Oct 01;32(5):597-622. DOI: https://doi.org/10.1210/er.2010-0016
45. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. JMC. 2003 Feb 25;46(6):883-908. DOI: https://doi.org/10.1021/jm020449y
46. Maximov P, M Lee T, Craig Jordan V. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013 May;8(2):135-55. DOI: https://doi.org/10.2174/1574884711308020006
47. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 1989 Nov 3;59(3):477-87. DOI: https://doi.org/10.1016/0092-8674(89)90031-7
48. Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, Toraldo G et al. The dynamic structure of the estrogen receptor. J Amino Acids. 2011 Jul 26;2011:812540. DOI: https://doi.org/10.4061/2011/812540
49. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000 Oct 14;14(2):121-41.
50. Sausville E, Carney D, Battey J. The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. JBC. 1985 Aug 25;260(18):10236-41.
51. Koide A, Zhao C, Naganuma M, Abrams J, Deighton-Collins S, Skafar DF et al. Identification of regions within the F domain of the human estrogen receptor α that are important for modulating transactivation and protein-protein interactions. Mol Endocrinol. 2007 Apr 01;21(4):829-42. DOI: https://doi.org/10.1210/me.2006-0203
52. Luisi BF, Xu W, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature. 1991 Aug 8;352(6335):497-505. DOI: https://doi.org/10.1038/352497a0
53. Su Q, Hu S, Gao H, Ma R, Yang Q, Pan Z et al. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology. 2008;75(3-4):159-68.DOI: https://doi.org/10.1159/000159267
54. Fuentes N, Silveyra P. Endocrine regulation of lung disease and inflammation. Exp Biol Med. 2018 Dec 3;243(17-18):1313-22. DOI: https://doi.org/10.1177/1535370218816653
55. Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A. Distinct nongenomic signal transduction pathways controlled by 17β-estradiol regulate DNA synthesis and cyclin D1 gene transcription in HepG2 Cells. Mol Bio Cell. 2002 Oct;13(10):3720-9.DOI: https://doi.org/10.1091/mbc.e02-03-0153
56. Le Dily F, Beato M. Signaling by steroid hormones in the 3D nuclear space. IJMS:Int J Mol Sci. 2018 Jan 23;19(2):306. DOI: https://doi.org/10.3390/ijms19020306
57. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001 Jul 15;29(14):2905-19. DOI: https://doi.org/10.1093/nar/29.14.2905
58. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiological Rev. 2001 Jul 01;81(3):1269-1304. DOI: https://doi.org/10.1152/physrev.2001.81.3.1269
59. Göttlicher M, Heck S, Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med. 1998 Jan 18;76(7):480-9. DOI: https://doi.org/10.1007/s001090050242
60. Ho KJ, Liao JK. Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol. 2002 Dec 01;22(12):1952-61. DOI: https://doi.org/10.1161/01.atv.0000041200.85946.4a
61. O’Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004 Aug;18(8):1859-75. DOI: https://doi.org/10.1210/me.2003-0044
62. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005 Apr;19(4):833-42. DOI: https://doi.org/10.1210/me.2004-0486
63. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell. 1990 Dec 20;63(6):1267-76.DOI: https://doi.org/10.1016/0092-8674(90)90422-b
64. Fujimoto N, Honda H, Kitamura S. Effects of environmental estrogenic chemicals on AP1 mediated transcription with estrogen receptors α and β.  J Steroid Biochem Mol Biol. 2004 Jan;88(1):53-9. DOI: https://doi.org/10.1016/j.jsbmb.2003.10.006
65. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 1997 Sep 5;277(5331):1508-10. DOI: https://doi.org/10.1126/science.277.5331.1508
66. Acconcia F, Ascenzi P, Bocedi A,  Spisni E, Tomasi V, Trentalance A et al. Palmitoylation-dependent estrogen receptor α membrane localization: regulation by 17β-estradiol. Mol Biol Cell. 2005 Jan 01;16(1):231-7. DOI: https://doi.org/10.1091/mbc.e04-07-0547
67. Lösel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003 Jan 01;4(1):46-55. DOI: https://doi.org/10.1038/nrm1009
68. Barton M, Filardo EJ, Lolait SJ, Thomas P, Maggiolini M, Prossnitz ER. Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol. 2018 Feb;176:4-15. DOI: https://doi.org/10.1016/j.jsbmb.2017.03.021
69. Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology .2012 Jul 01;153(7):2953-62. DOI: https://doi.org/10.1210/en.2012-1061
70. Tang ZR, Zhang R, Lian ZX, Deng SL, Yu K. Estrogen-receptor expression and function in female reproductive disease. Cells. 2019 Sep 21;8(10):1123. DOI: https://doi.org/10.3390/cells8101123
71. Tang Z, Kang B, Li C, Chen T, Zhang Z.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019 Jul 2;47(1):556-560. DOI: https://doi.org/10.1093/nar/gkz430
72. Liu B. The role of GRK2 in hypertension and regulation of GPR30. Electronic Thesis and Dissertation Repository at Western Uni. 2012 Jun;578
73. Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N et al. Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer. 2010 Oct 15;127(8):1748-57. DOI: https://doi.org/10.1002/ijc.25207
74. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G et al. Mechanisms of estrogen action. Physiol Rev. 2001 Oct;81(4):1535-65. DOI: https://doi.org/10.1152/physrev.2001.81.4.1535
75. Lonard DM, O’malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell. 2007 Sep 7;27(5):691-700. DOI: https://doi.org/10.1016/j.molcel.2007.08.012
76. Oñate SA, Tsai SY, Tsai MJ, O’Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995 Nov 24;270(5240):1354-7. DOI: https://doi.org/10.1126/science.270.5240.1354
77. Lonard DM, O’Malley BW. The expanding cosmos of nuclear receptor coactivators. Cell. 2006 May 5;125(3):411-4. DOI: https://doi.org/10.1016/j.cell.2006.04.021
78. Manavathi B, Samanthapudi VS, Gajulapalli VN. Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front. Cell Dev Biol. 2014 Aug 12;2:34. DOI: https://doi.org/10.3389/fcell.2014.00034
79. Lonard DM, O’Malley BW. Emerging roles of the ubiquitin proteasome system in nuclear hormone receptor signaling. Prog Mol Biol Transl Sci. 2009 Oct 7;87:117-135.DOI: https://doi.org/10.1016/S1877-1173(09)87004-X